Briefs
Trinity Life Sciences, a leader in global life sciences commercialization solutions, released its third annual TGaS Digital Marketing Competency Report assessing 150+ biopharma brands through the lens of digital marketing patient/caregiver experiences. The study evaluates the brands across five categories and more than 100 characteristics to understand each one’s digital marketing presence and establish a brand digital competency ranking.
Learn what sets some brands apart from others. To download the excerpt of the report with the ranking of all 150+…
Read Now
Blog
Published November 12, 2024
Trinity Life Sciences recently attended the HLTH 2024 conference in Las Vegas. The conference focused on “pushing boundaries to transform the next decade of health” and united stakeholders across the entire healthcare ecosystem, including life sciences professionals, providers, payers, government, healthcare policymakers, investors and more. Trinity’s Customer Engagement team participated in workshops and discussions to hear the latest from our peers, other industry leaders and sponsors – here are our key takeaways from HTLH 2024:
Moving from Multichannel to Omnichannel …
Read Now
Briefs
The healthcare industry has long been known for its significant environmental impact, including contributing ~5% of total global emissions. As awareness of this impact has increased, life sciences companies are now actively committing to climate resilience and environmental sustainability through various initiatives, including net-zero commitments.
Trinity Life Sciences has identified several recent trends driving this shift including increasing Health Technology Assessment (HTA) requirements, investment reporting, patient and healthcare provider (HCP) demands for greener options, heightened awareness of waste and a…
Read Now
Webinars
Available On Demand
Generative AI is having a transformative impact on the pharmaceutical industry. Drugmakers are partnering up with companies like Insilico Medicine, Exscientia, BenevolentAI, and more to leverage their respective generative AI-powered platforms and applying them across the pharma value chain: from accelerating drug discovery and optimizing clinical trials, to improving operational efficiencies and enabling personalized treatments that promise better outcomes.
What progress has been made by the pharma companies in integrating generative AI into their operations and what advances would we…
Watch Now
Blog
Published November 5, 2024
What is data operationalization, and why is it important in life sciences?
The ability to integrate insights from your data into your business workflows is commonly referred to as data operationalization.
Throughout life sciences organizations, functional needs and behaviors have evolved, making data operationalization at scale a vital source of competitive advantage for life sciences.
It is no longer enough to derive business strategy from data to ensure a competitive advantage. Executives now expect real-time updates from the market—and patients…
Read Now
Briefs
Joint clinical assessment (JCA) is a European Union (EU) initiative intended to improve patient access to health technologies in Europe through a harmonized clinical health technology assessment (HTA) process. From January 2025, all new oncology medicines and advanced therapy medicinal products will go through the JCA process, followed by all orphan medicinal products from 2028 and all new medicines from 2030.
The JCA process will run parallel to European Medicines Agency (EMA) regulatory evaluation and will involve submission of a…
Read Now
Briefs
The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research organization dedicated to assessing the value of healthcare interventions, including diagnostics, devices, digital therapeutics and prescription drugs. Although ICER’s assessments do not represent a mandate for product funding or pricing in the U.S. in the same way as, for example, National Institute for Health and Care Excellence (NICE) assessments in the U.K., public reports on a product’s value are bound to influence discussions and negotiations between payers…
Read Now
Webinars
Available On Demand
Patient finding is more than a buzzword. Ready to challenge the status quo?
With more data, advancements in AIML and greater access to insights, it is not surprising that patient finding is evolving. Many pharma organizations have deep-rooted ideas about what patient finding requires, but they often miss the opportunity to put the patient at the center. Join Trinity Life Sciences’ experts as we debunk common misconceptions and discuss the actionable potential of patient finding throughout the drug development lifecycle. We…
Watch Now
White Papers
The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023).
This was driven by notable improvements in “Specialty and Large Market” products (36% overperformed vs. 18% average in years prior) and First Launch Companies (33% overperformed vs. 20% in years prior).
The needle is moving.
Complete the form below to access the full white paper
By submitting…
Read Now
White Papers
The National Reimbursement Drug List (NRDL) negotiations are expected to conclude by November 2024, with pricing outcomes gradually being revealed starting in January 2025. The Trinity Life Sciences team has reviewed the 2023 NRDL inclusion and pricing results, drawing some key learnings.
Key Takeaways from the 2023 NRDL Update
Continued importance of the NRDL
Accelerated access for innovative drugs
Evolving NRDL policy and payer landscape
Complete the form below to access the full white paper
By submitting this form, creating…
Read Now
